
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is a clinical-stage biotechnology company developing innovative therapeutics to treat chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. Through its lead candidate, obefazimod, the company is targeting ulcerative colitis and Crohn's disease. With a strong efficacy and safety profile, backed by positive clinical trials and expert support, Abivax is poised for success in the $30 billion IBD market. The recent positive Part 2 maintenance readout, increased UC revenue estimates, and strengthened balance sheet through an equity financing contribute to our bullish outlook on the stock.
Bears say
Abivax is facing intense pressure in the biotech industry as it races to bring its drug candidate, obefazimod, to the market for the treatment of inflammatory bowel diseases. Despite positive feedback from key opinion leaders, concerns about the company's financial situation and the upcoming catalysts have led to a negative outlook from financial analysts. With only one operating segment focused on R&D, Abivax may struggle to generate sufficient financial resources to support its pipeline, making it a high-risk investment.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares